Itching is predominant feature in many inflammatory and tumor related skin diseases.
The only treatment we have for it is anti-histamines, unfortunately for many people this does not relieve their symptoms. This suggests that there are other mechanisms going on triggering these symptoms. In the most recent Journal of Allergy and Clinical Immunololgy, they look into a histamine independent therapeutic strategy, IL-31. They studied its receptor IL-31RA. They activated TH 2 pathways and found that in patients with atopic dermatitis, IL-31RA levels were highest. This could lead to new targeted therapy for itching, with cytokines used to block these pathways when anti-histamines fail.